Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) announces that it has entered into two agreements related to the manufacturing of drug substance for its upcoming Phase IIa clinical trial where lead asset, ISLA-101 will be studied as a potential preventative for dengue fever. Island has entered into a one-off purchase agreement with CerRx, Inc. to acquire up to 5kgs of Active Pharmaceutical Ingredient (API). In addition, Island has engaged Curia (formerly Albany Molecular Research, Inc.) to process the API on a one-off basis. Upon obtaining the final GMP API, the drug substance will be formulated into patient ready drug product for use in the upcoming Phase II clinical trial. CEO of Island Pharmaceuticals, Dr David Foster said, “I am very pleased that we have been able to acquire the drug substance needed for our ISLA-101 trial so quickly. This solution with our partners at CerRx and Curia enables Island to advance an efficient GMP manufacturing campaign more quickly and at substantially lower cost than initially anticipated. Based on current timelines, we remain on track to initiate a Phase II dengue fever trial later in 2021.” Aurea lead Series C equity raise and is a reference investor in Island Pharmaceuticals. Click on the links below for more information.
top of page
bottom of page
Comentarios